Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.

Inoue T, Anai S, Onishi S, Miyake M, Tanaka N, Hirayama A, Fujimoto K, Hirao Y.

BMC Urol. 2013 Jan 5;13:1. doi: 10.1186/1471-2490-13-1.

2.

Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.

Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, Goodison S, Mizokami A, Rosser CJ.

J Urol. 2007 May;177(5):1913-7.

PMID:
17437847
3.

Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.

Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann HP.

Radiother Oncol. 2007 Feb;82(2):229-38. Epub 2007 Jan 4.

PMID:
17207548
4.

Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.

Arafat W, Zhou T, Naoum GE, Buchsbaum DJ.

J Egypt Natl Canc Inst. 2015 Dec;27(4):205-15. doi: 10.1016/j.jnci.2015.08.003. Epub 2015 Sep 16.

5.

Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.

Wen B, Deutsch E, Eschwege P, De Crevoisier R, Nasr E, Eschwege F, Bourhis J.

J Urol. 2003 Nov;170(5):2036-9.

PMID:
14532848
6.
7.

Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.

Konsoula Z, Cao H, Velena A, Jung M.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1541-8. doi: 10.1016/j.ijrobp.2010.11.057. Epub 2011 Jan 27.

PMID:
21277099
8.

Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.

Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ.

Clin Cancer Res. 2000 Jun;6(6):2513-20.

9.

The radiosensitizing effect of Paeonol on lung adenocarcinoma by augmentation of radiation-induced apoptosis and inhibition of the PI3K/Akt pathway.

Lei Y, Li HX, Jin WS, Peng WR, Zhang CJ, Bu LJ, Du YY, Ma T, Sun GP.

Int J Radiat Biol. 2013 Dec;89(12):1079-86. doi: 10.3109/09553002.2013.825058. Epub 2013 Oct 25.

PMID:
23875954
10.
11.

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer.

Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N, Oya M.

Br J Cancer. 2012 Aug 7;107(4):652-7. doi: 10.1038/bjc.2012.321. Epub 2012 Jul 17.

12.
13.
16.

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.

Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A.

Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1507-12.

PMID:
11121656
17.
18.

Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.

Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A.

Urology. 2005 Dec;66(6):1239-44.

PMID:
16360450
19.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
20.

Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.

Lee YJ, Seol JW, Jeong JK, Moon MH, Park SY.

Mol Med Rep. 2011 Nov-Dec;4(6):1255-9. doi: 10.3892/mmr.2011.558. Epub 2011 Aug 16.

PMID:
21850375

Supplemental Content

Support Center